Companies: 10,795·Total market cap: $144.5T
E-therapeutics Plc

E-therapeutics Plc

ETXPFOTCHealthcare
$0.13
+$0.00(+0.00%)
Market Cap$75963547
P/E Ratio—
52W High$0.13
52W Low$0.13
Overview

E-therapeutics Plc (ETXPF) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

ETXPF · cash on hand · updated Jan 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$32.7M▲ +58.3% vs prior year
FY · as of Jan 31, 2025 · Reported in GBP
Cash & Cash Equiv. (CCE)
$20.5M
cashAndCashEquivalents
Short-Term Investments
$12.2M
shortTermInvestments
YoY Change vs Prior Year
+58.3%
vs prior fiscal year
Latest Quarter
$32.7M
Q1 2025
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in GBP

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: January 31, 2025

Net cash vs debt

Cash & ST Investments$32.7MCash on Hand
Total Debt$317,000Total Debt
Net Cash / Net Debt+$32.4MNet Cash Position
Cash vs Debt Ratio
Cash 99%Debt 1%

E-therapeutics Plc has a net cash position of $32.4M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$32.7M − $317,000 = +$32.4M

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
ETXPF annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Jan 31, 2025Latest$32.7M+58.3%
Jan 31, 2024$20.7M-34.8%
Jan 31, 2023$31.7M-10.7%
Jan 31, 2022$35.5M+98.4%
Jan 31, 2021$17.9M+253.3%
ETXPF cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.6%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.5%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
E-therapeutics Plc
E-therapeutics PlcYOU
ETXPF
$32.7M43.1%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

E-therapeutics Plc (ETXPF) cash on hand as of January 31, 2025 is $32.7M, comprising $20.5M in cash and cash equivalents (CCE) plus $12.2M in short-term investments — reported as E-therapeutics Plc cash and short-term investments on the balance sheet (10-K filing). Also referred to as E-therapeutics Plc cash reserves or cash position.

E-therapeutics Plc annual cash on hand history shows increased +58.3% in 2025: increased +58.3% in 2025. E-therapeutics Plc cash reserves in 2025 reflect the company's capital allocation strategy.

E-therapeutics Plc carries total debt of $317,000 against cash of $32.7M, resulting in a net cash position of +$32.4M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

ETXPF cash on hand · 5 questions

As of January 31, 2025, E-therapeutics Plc (ETXPF) has $32,723,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $20,519,000 in cash and cash equivalents (CCE) plus $12,204,000 in short-term investments. Latest quarter (January 31, 2025): $32,723,000. Data sourced from the annual 10-K filing via FMP.

ETXPF cash on handETXPF cash reservesETXPF cash 2025how much cash does ETXPF have

▸ Source: FMP /balance-sheet-statement · US GAAP · E-therapeutics Plc · E-therapeutics Plc SEC 10-K & 10-Q filings · US GAAP · Last updated: January 31, 2025